# A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines

> **NCT05048342** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 71 (actual)

## Conditions studied

- Chronic Spontaneous Urticaria

## Interventions

- **DRUG:** LOU064

## Key facts

- **NCT ID:** NCT05048342
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-15
- **Primary completion:** 2023-12-08
- **Final completion:** 2023-12-09
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2025-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05048342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05048342, "A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05048342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*